blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1675836

EP1675836 - DERIVATIVES OF 4-PHENYLTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY [Right-click to bookmark this link]
Former [2006/27]DERIVATIVES OF 4-PHENYLTHIAZOLES AND 4-PHENYLIMIDAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY
[2015/51]
StatusNo opposition filed within time limit
Status updated on  17.02.2017
Database last updated on 03.10.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
IPSEN PHARMA
65 Quai Georges Gorse
92100 Boulogne-Billancourt / FR
[2009/11]
Former [2006/27]For all designated states
Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.)
42, rue du Docteur Blanche
75016 Paris / FR
Inventor(s)01 / CHABRIER DE LASSAUNIERE, Pierre-Etienne
134, quai Louis Blériot
F-75016 Paris / FR
02 / HARNETT, Jeremiah
32, allée de la Bergerie
F-91190 Gif-sur-Yvette / FR
03 / BIGG, Dennis
12, rue des Bénédictines
F-91190 Gif-sur-Yvette / FR
04 / LIBERATORE, Anne-Marie
10, rue de la Croix Picard
F-78610 Auffargis / FR
05 / THURIEAU, Christophe
10 Bld Emile Augier
F-75116 Paris / FR
06 / DONG, Zheng, Xin
66 Fairview Street
Holliston, MA 01746 / US
 [2006/27]
Representative(s)Audonnet, Nathalie, et al
Ipsen Pharma
Direction Propriété Intellectuelle
65 quai Georges Gorse
92650 Boulogne Billancourt Cedex / FR
[2016/15]
Former [2010/33]Audonnet, Nathalie, et al
Ipsen Pharma Direction Propriété Intellectuelle 65 quai Georges Gorse
92650 Boulogne Billancourt Cedex / FR
Former [2006/27]Bourgouin, André
Ipsen - S.C.R.A.S., 24, rue Erlanger
75781 Paris Cedex 16 / FR
Application number, filing date04791489.008.10.2004
[2006/27]
WO2004FR02537
Priority number, dateUS2003068100208.10.2003         Original published format: US 681002
US2004091500110.08.2004         Original published format: US 915001
[2006/27]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2005035510
Date:21.04.2005
Language:FR
[2005/16]
Type: A1 Application with search report 
No.:EP1675836
Date:05.07.2006
Language:FR
The application published by WIPO in one of the EPO official languages on 21.04.2005 takes the place of the publication of the European patent application.
[2006/27]
Type: B1 Patent specification 
No.:EP1675836
Date:13.04.2016
Language:FR
[2016/15]
Search report(s)International search report - published on:EP21.04.2005
ClassificationIPC:C07D277/28, A61K31/426, A61P25/28, A61P29/00, A61P25/08
[2015/51]
CPC:
C07D233/64 (EP,US); A61K31/417 (EP,US); A61K31/4178 (EP,US);
A61K31/42 (EP,US); A61K31/421 (EP,US); A61K31/426 (EP,US);
A61K31/427 (EP,US); A61K31/454 (EP,US); A61K31/496 (EP,US);
A61P25/08 (EP); A61P25/28 (EP); A61P29/00 (EP);
C07D233/50 (EP,US); C07D261/04 (EP,US); C07D263/32 (EP,US);
C07D277/24 (EP,US); C07D277/28 (EP,US); C07D277/34 (EP,US);
C07D401/06 (EP,US); C07D403/06 (EP,US); C07D405/06 (EP,US);
C07D409/06 (EP,US); C07D413/06 (EP,US); C07D417/04 (EP,US);
C07D417/06 (EP,US); C07D417/14 (EP,US) (-)
Former IPC [2006/27]C07D277/28, C07D233/54, C07D417/04, A61K31/427, A61K31/417, A61P25/28, A61P29/00, A61P25/08
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/15]
Former [2006/27]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:DERIVATE VON 4-PHENYLTHIAZOLEN UND DEREN VERWENDUNG ALS MEDIKAMENTE ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN, SCHMERZEN UND EPILEPSIE[2015/51]
English:DERIVATIVES OF 4-PHENYLTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY[2015/51]
French:DERIVES DU 4-PHENYLTHIAZOLE ET LEUR UTILISATION COMME MEDICAMENTS POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES, LA DOULEUR ET L'EPILEPSIE[2015/51]
Former [2006/27]DERIVATE VON 4-PHENYLTHIAZOLEN UND 4-PHENYLIMIDAZOLEN UND DEREN VERWENDUNG ALS MEDIKAMENTE ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN, SCHMERZEN UND EPILEPSIE
Former [2006/27]DERIVATIVES OF 4-PHENYLTHIAZOLES AND 4-PHENYLIMIDAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY
Former [2006/27]DERIVES DU 4-PHENYLTHIAZOLE ET DU 4-PHENYLIMIDAZOLE ET LEUR UTILISATION COMME MEDICAMENTS POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES, LA DOULEUR ET L'EPILEPSIE
Entry into regional phase08.05.2006National basic fee paid 
08.05.2006Designation fee(s) paid 
08.05.2006Examination fee paid 
Examination procedure08.05.2006Examination requested  [2006/27]
20.04.2012Despatch of a communication from the examining division (Time limit: M04)
21.08.2012Reply to a communication from the examining division
12.09.2012Despatch of a communication from the examining division (Time limit: M06)
12.07.2013Reply to a communication from the examining division
23.10.2013Despatch of a communication from the examining division (Time limit: M04)
06.06.2014Reply to a communication from the examining division
11.03.2015Cancellation of oral proceeding that was planned for 16.04.2015
20.03.2015Despatch of a communication from the examining division (Time limit: M02)
16.04.2015Date of oral proceedings (cancelled)
26.06.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
06.08.2015Reply to a communication from the examining division
08.12.2015Communication of intention to grant the patent
17.02.2016Fee for grant paid
17.02.2016Fee for publishing/printing paid
17.02.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.04.2012
Opposition(s)16.01.2017No opposition filed within time limit [2017/12]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
06.08.2015Request for further processing filed
06.08.2015Full payment received (date of receipt of payment)
Request granted
24.08.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
06.06.2014Request for further processing filed
06.06.2014Full payment received (date of receipt of payment)
Request granted
08.07.2014Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
12.07.2013Request for further processing filed
12.07.2013Full payment received (date of receipt of payment)
Request granted
25.07.2013Decision despatched
Fees paidRenewal fee
31.10.2006Renewal fee patent year 03
31.10.2007Renewal fee patent year 04
31.10.2008Renewal fee patent year 05
02.11.2009Renewal fee patent year 06
02.11.2010Renewal fee patent year 07
31.10.2011Renewal fee patent year 08
31.10.2012Renewal fee patent year 09
31.10.2013Renewal fee patent year 10
31.10.2014Renewal fee patent year 11
02.11.2015Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.10.2004
AT13.04.2016
BG13.04.2016
CY13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
MC13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
TR13.04.2016
GR14.07.2016
PT16.08.2016
IE08.10.2016
LU08.10.2016
BE31.10.2016
[2018/38]
Former [2018/29]HU08.10.2004
AT13.04.2016
CY13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
MC13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
TR13.04.2016
GR14.07.2016
PT16.08.2016
IE08.10.2016
LU08.10.2016
BE31.10.2016
Former [2018/28]HU08.10.2004
AT13.04.2016
CY13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
MC13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
GR14.07.2016
PT16.08.2016
IE08.10.2016
LU08.10.2016
BE31.10.2016
Former [2017/51]AT13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
GR14.07.2016
PT16.08.2016
IE08.10.2016
LU08.10.2016
BE31.10.2016
Former [2017/47]AT13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
GR14.07.2016
PT16.08.2016
LU08.10.2016
BE31.10.2016
Former [2017/37]AT13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SI13.04.2016
SK13.04.2016
GR14.07.2016
PT16.08.2016
BE31.10.2016
Former [2017/10]AT13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
SK13.04.2016
GR14.07.2016
PT16.08.2016
BE31.10.2016
Former [2017/09]AT13.04.2016
CZ13.04.2016
DK13.04.2016
EE13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
RO13.04.2016
SE13.04.2016
GR14.07.2016
PT16.08.2016
Former [2017/07]AT13.04.2016
DK13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
SE13.04.2016
GR14.07.2016
PT16.08.2016
Former [2016/52]AT13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
SE13.04.2016
GR14.07.2016
PT16.08.2016
Former [2016/51]AT13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
GR14.07.2016
PT16.08.2016
Former [2016/50]AT13.04.2016
FI13.04.2016
NL13.04.2016
PL13.04.2016
Former [2016/49]FI13.04.2016
NL13.04.2016
PL13.04.2016
Cited inInternational search[DX]WO0126656  (SOD CONSEILS RECH APPLIC [FR], et al) [DX] 1-10 * the whole document *;
 [X]WO02083656  (SOD CONSEILS RECH APPLIC [FR], et al) [X] 1-10 * claims 1-10; compounds 3, 79 *;
 [X]WO03009843  (SOD CONSEILS RECH APPLIC [FR], et al) [X] 1-5 * compound 5 *;
 [PX]WO2004011402  (SOD CONSEILS RECH APPLIC [FR], et al) [PX] 1-10* exemple 1, intermediaire 1.2) page 34 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.